Merck (NYSE:MRK) said that data from a pair of late-stage trials showed that an oral, two-drug regimen of ...

MSD’s HIV treatment is now back on track after an earlier hit which saw the FDA place a clinical hold on the therapy.

The combination demonstrated non-inferiority to comparator antiretroviral therapies, meeting the primary efficacy success ...

New data from the MK-8591A-051 and MK-8591A-052 trials, both investigating the efficacy and safety of 100-mg doravirine and 0.25-mg islatravir as a once-daily 2-drug regimen for virologically ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Gilead released data showing that an HIV drug, called lenacapavir, could provide virtually complete protection against ...

Gilead Sciences, Inc. (NASDAQ:GILD) presented data from its HIV treatment portfolio and pipeline at the Conference on ...

“I’m excited to see that DOR/ISL has potential as a new daily treatment option for people living with HIV who may benefit from this two-drug regimen.” Islatravir, Merck’s investigational ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its ...

Merck (MRK) announced the presentation of “positive” results from two pivotal Phase 3 trials of the investigational, once-daily, oral, two-drug ...

Previously reported results demonstrated the efficacy of both antiretroviral regimens. The newly presented data shows that Biktarvy maintained high rates of HIV-1 (95.4%) and HBV (86.6% ...